MK-4280A-008: A phase 3 trial of favezelimab/pembrolizumab compared to chemotherapy in relapsed or refractory classical Hodgkin lymphoma

This phase three trial is testing favezelimab/pembrolizumab in people with relapsed or refractory classical Hodgkin lymphoma.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05508867

Trial aim and background 

The aim of this trial is to compare the effectiveness of favezelimab/pembrolizumab (MK-4280A) against either the chemotherapy drug bendamustine or gemcitabine in adults with classical Hodgkin lymphoma that has either come back (relapsed) or not responded to previous treatment (refractory). It will also test the safety profile and side effects of favezelimab/pembrolizumab (MK-4280A).

The trial predicts that MK-4280A will be superior to other chemotherapy choices in terms overall survival.

Patients in the study will either receive MK-4280A or their physicians choice of bendamustine or gemcitabine.

Who can enter

Patients aged over 18 with classical HL which has relapsed or is refractory and have exhausted all known treatment options may be eligible for this trial

Locations

Recruitment is taking place in the following UK locations:

  • Leicester Royal Infirmary, Leicester
  • St Bartholomew's Hospital, London
  • Oxford, Oxfordshire
  • Derriford Hospital, Plymouth

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT05508867 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.